Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
JHEP Reports : Innovation in Hepatology|October 18, 2021
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa studyHaiyan Ma, Tien Huey Lim, Apinya Leerapun, et al.
Hemasphere|October 15, 2021
Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma AllianceStephen Boyle, Joshua W D Tobin, Jacinta Perram, et al.
Trials|September 24, 2025
The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver diseaseLeon A Adams, Deborah de Guingand, Gary P Jeffrey, et al.
Alimentary Pharmacology & Therapeutics|May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levelsSamuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
Gastroenterology|October 15, 2014
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infectionGregory J Dore, Eric Lawitz, Christophe Hézode, et al.
NEJM Evidence|January 28, 2025
Larsucosterol for the Treatment of Alcohol-Associated HepatitisMitchell Shiffman, Ben Da, Aparna Goel, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Springerplus|September 3, 2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Graham R Foster, Kazuaki Chayama, Wan-Long Chuang, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Pageof 15